Vaxart (NASDAQ:VXRT) Given New $2.00 Price Target at B. Riley

Vaxart (NASDAQ:VXRT) had its target price lowered by B. Riley from $2.50 to $2.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s target price points to a potential upside of 339.85% from the company’s previous close.

Vaxart Stock Performance

Shares of Vaxart stock traded down $0.01 during trading on Thursday, reaching $0.45. 1,397,402 shares of the company’s stock were exchanged, compared to its average volume of 2,372,299. The firm’s 50-day moving average price is $0.63 and its 200 day moving average price is $0.70. The company has a market cap of $103.44 million, a P/E ratio of -1.11 and a beta of 1.69. Vaxart has a 1-year low of $0.45 and a 1-year high of $1.41.

Vaxart (NASDAQ:VXRT) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The firm had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $15.68 million. As a group, equities research analysts predict that Vaxart will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd grew its position in Vaxart by 869.3% during the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 122,387 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after purchasing an additional 346,725 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 17,942 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 251,789 shares during the last quarter. 18.05% of the stock is currently owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.